Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Amerikaanse aandelen  /  Hemispherx BioPharma, Inc (Public, AMEX:HEB)

Ontvang nu dagelijks onze kooptips!

word abonnee

Amerikaanse aandelen« Terug naar discussie overzicht

Hemispherx BioPharma, Inc (Public, AMEX:HEB)

13.337 Posts
Pagina: «« 1 ... 662 663 664 665 666 667 »» | Laatste | Omlaag ↓
  2. [verwijderd] 12 maart 2010 13:02
    quote:

    sjef 01 schreef:

    Sander,

    HEB je ze nu wel of niet..?

    Op basis van omzet kan je interpreteren en koers kan je vermoeden dat je een outpuke hebt te pakken.. Kan ook een angstige shortshow zijn.. en dan kakken we weer in..
    Nee Sjef. HEB en CXM beide verkocht. HEB medio febr. Ik heb HEB verkocht obv de negativiteit rondom het aandeel qua resultaten.
    HEB gaat de dollar in denk ik en ik zou met CXM zeer alert zijn!
  6. drulletje drie 16 maart 2010 09:05
    denk persoonlijk niet op dat nieuws lopen al meer van die zaken en daar deed de koers vrij weinig op!

    denk dat de cijfers de daling hebben veroorzaakt!

    finance.yahoo.com/news/Hemispherx-Bio...

    Hemispherx Biopharma Announces 2009 Financial Results
    Cash and Cash Equivalent Increase 9 Fold Over Prior Year

    Press Release Source: Hemispherx Biopharma, Inc. On Monday March 15, 2010, 8:00 am EDT

    PHILADELPHIA, March 15, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced its financial results for the fiscal year ended December 31, 2009. The net loss for the year (including non-cash charges) was approximately $13,438,000 or $0.12 per share as compared to a net loss of $12,219,000 or $0.16 per share in 2008. This $1,219,000 increase in loss was primarily due to increased research and development expenses associated with preparing the New Brunswick, New Jersey manufacturing plant for increased production plus efforts employed in supporting the New Drug Application ("NDA") and employee compensation awards.

    Cash and cash equivalents were $58,072,000 as of December 31, 2009 reflecting an increase of $51,953,000 since year end 2008 due primarily to equity financing during 2009. Cash used in operating activities for the year ended December 31, 2009 was $9,297,000 compared to $9,358,000 for the same period in 2008, a reduction of $61,000.

    Progress was made in preparing the Company's production facilities, including the Company's contract manufacturer, for various FDA inspections and additional preclinical studies were conducted assessing the potential use of Ampligen(R), an experimental therapeutic, and Alferon NTM (FDA approved for a category of sexually transmitted diseases) against influenza and certain other disease conditions. Alferon NTM production is expected to be resumed based on an approximate $4.4 Million investment in various facility improvements in our approximate 43,000 square foot New Jersey manufacturing facility. A Complete Response Letter received on November 25, 2009, from the Food and Drug Administration ("FDA") regarding the pending NDA has prompted a broad internal and external program to design and implement a confirmatory clinical trial in chronic fatigue syndrome ("CFS") and to conduct certain additional preclinical tests.
  18. [verwijderd] 26 januari 2012 17:00

    Sindsdien ook al zeer laag gevallen maar vandaag veert Heb op) met +20,04% naar $0.31 nadat het voor Alferon onder het merknaam "Naturaferon" in Argentinië de goedkeuring heeft verkregen om het te verdelen en te verkopen.

    Jan. 26, 2012, 8:30 a.m. EST
    Hemispherx Biopharma Gains Regulatory Approval in Latin America

    Alferon(R) Under the Brand Name "Naturaferon" Approved in Argentina

    PHILADELPHIA, Jan 26, 2012 (GlobeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. HEB +19.38% (the "Company" or "Hemispherx") today announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, has approved the sale and distribution of Alferon N Injection(R) (under the brand name "Naturaferon") in Argentina. In June 2010, Hemispherx agreed to provide GP Pharm an option to market Alferon N Injection(R), its FDA-approved natural interferon, in Argentina and other Latin America countries. In December 2010, GP Pharm exercised this right and in July 2011 GP Pharm submitted an application for approval to ANMAT. Alferon N Injection(R) (Interferon alfa-n3 (human leukocyte derived)) is already approved in the US for the treatment of refractory or recurring external condylomata acuminate (genital warts) in patients 18 years of age or older. A major multi-million dollar investment scale-up of Alferon N Injection(R) manufacturing is underway at Hemispherx's New Brunswick, NJ facility.

    According to a World Health Organization report on Human Papillomavirus (HPV), "Genital warts are very common and are highly infectious, and between 90% and 100% are caused by HPV genotypes 6 and 11. Although they do not usually result in death, genital warts cause significant morbidity and entail substantial health care costs. Recurrence is common."

    Mr. Thomas Equels, Executive Vice Chairman of Hemispherx, stated "This approval is the result of Hemispherx's global business development initiatives which it plans to continue and to expand. It also reflects the increased capability of Hemispherx clinical and regulatory team to manage regulatory environments outside the US and to gear up to comply with import-export regulations in various countries. We are confident about the commercial opportunities for Alferon N Injection(R) in Argentina and pleased with the progress GP Pharm has made as is evidenced by this approval and parallel programs planned for Latin America."

    Dr. Jorge Candal, Medical Director of GP Pharm, said, "We are pleased that ANMAT has understood the effectiveness of the unique technology platform represented by Alferon N Injection(R). We believe it can make a significant health impact in the lives of numerous patients in Argentina."

    Jorge Braver, President of GP Pharm, said, "We are very excited about the approval of Alferon N in Argentina, and we look forward to providing it to patients in Argentina who will benefit from this unique, natural interferon."

    Hemispherx continues to undertake its projected approximately $6.5 million expansion to its Good Manufacturing Process (GMP) manufacturing facility in New Brunswick, New Jersey including capital improvements, system upgrades and the introduction of building management systems to enhance production of our three products: Alferon N Injection(R), Alferon(R) LDO and Ampligen(R). One of the primary goals for these enhancements to our FDA licensed facility is to accommodate larger production volumes of Alferon N Injection(R) for anticipated global requirements.

    www.marketwatch.com/story/hemispherx-...

    Skip

13.337 Posts
Pagina: «« 1 ... 662 663 664 665 666 667 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 910,18 -0,52%
EUR/USD 1,0857 -0,01%
FTSE 100 8.385,10 -0,46%
Germany40^ 18.675,60 -0,50%
Gold spot 2.426,03 -0,01%
NY-Nasdaq Composite 16.794,87 +0,65%

Stijgers

Flow T...
+1,74%
SBM Of...
+1,73%
INPOST
+1,29%
OCI
+1,08%
RENEWI
+0,67%

Dalers

Alfen ...
-15,17%
Sif Ho...
-5,16%
FASTNED
-4,29%
AMG Cr...
-4,04%
Avantium
-3,68%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!